Recently, the United States Food and Drug Administration granted fast-track status to a phase 2 trial of the novel MDM2–p53 inhibitor alrizomadlin (APG-115), which demonstrated preliminary antitumor activity also in uveal melanoma [138]. The gene discussed is MDM2; the disease is uveal melanoma.